<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586544</url>
  </required_header>
  <id_info>
    <org_study_id>1131374-2</org_study_id>
    <nct_id>NCT03586544</nct_id>
  </id_info>
  <brief_title>Reducing Exercise-induced Bronchoconstriction in Children With Asthma and Obesity</brief_title>
  <official_title>Asthma and Childhood Obesity: Understanding Potential Mechanisms and Identifying Strategies to Improve Respiratory Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nevada, Las Vegas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nevada, Las Vegas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Guidelines from the American Thoracic Society strongly recommend interval warm-up exercise&#xD;
      before planned exercise to reduce exercise-induced bronchoconstriction severity. However, no&#xD;
      empirical data on the effects of interval warm-up exercise on exercise-induced&#xD;
      bronchoconstriction severity are available in obese asthmatic children, where excess fat&#xD;
      exerts such an unfavorable burden on the respiratory system, particularly during exercise.&#xD;
      The objective of this study is to investigate the effects of interval warm-up exercise on&#xD;
      exercise-induced bronchoconstriction severity in obese and nonobese asthmatic children. Our&#xD;
      approach will be to investigate exercise tolerance, respiratory function, and&#xD;
      exercise-induced bronchoconstriction severity and the effects of (1) 8x30sec interval warm-up&#xD;
      &amp; (2) pretreatment with a bronchodilator compared with a no-treatment control on&#xD;
      exercise-induced bronchoconstriction severity in 8-12 yr, prepubescent, obese and nonobese&#xD;
      asthmatic children.&#xD;
&#xD;
      [Aim]: To investigate the effects of interval warm-up exercise on exercise-induced&#xD;
      bronchoconstriction severity. [Hypothesis]: Interval warm-up exercise will reduce&#xD;
      exercise-induced bronchoconstriction severity after an exercise challenge test to a similar&#xD;
      extent as bronchodilator and better than control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Note related to early termination: Although the intent of the study was to compare obese and&#xD;
      nonobese children, early termination precluded us from completing this analysis and thus the&#xD;
      pooled results are included in the results. The brief summary has been updated to reflect the&#xD;
      presented results.&#xD;
&#xD;
      The investigators will enroll prepubescent, 8 - 12 yr old, obese (body mass index &gt; 95th&#xD;
      percentile; N=25) and nonobese (body mass between 16th and 84th percentile; N=25) children&#xD;
      with mild asthma. The investigators will investigate the severity of exercise-induced&#xD;
      bronchoconstriction during planned exercise performed 15 minutes after the following three&#xD;
      conditions performed on separate days in a random order: (1) 8x30sec interval warm-up, (2)&#xD;
      short-acting beta agonist or albuterol, &amp; (3) control, in prepubescent, 8 - 12 yr old, obese&#xD;
      and nonobese children with mild asthma.&#xD;
&#xD;
      The investigators will measure the following in all participants:&#xD;
&#xD;
        1. Pulmonary function: spirometry, lung volumes, diffusing capacity of lung for carbon&#xD;
           monoxide, maximum voluntary ventilation, maximal inspiratory and expiratory pressures,&#xD;
           airway resistance, and expired nitric oxide&#xD;
&#xD;
        2. Exercise tolerance during graded cycle ergometry: Gas exchange, ventilation, heart rate,&#xD;
           blood pressure, pulse oximetry, electrocardiogram&#xD;
&#xD;
        3. Ratings of perceived breathlessness and exercise induced bronchoconstriction in response&#xD;
           to a 6 minute high-intensity exercise challenge after three conditions performed on&#xD;
           three separate days:&#xD;
&#xD;
      Three conditions that will precede the exercise challenge include:&#xD;
&#xD;
        1. 8x30sec of interval warm-up 15min prior to exercise challenge: This includes eight 30sec&#xD;
           bouts of high-intensity interval exercise at 85-95% of HRmax, with 45sec of recovery&#xD;
           between.&#xD;
&#xD;
        2. Two puffs of albuterol 15 min prior to exercise challenge&#xD;
&#xD;
        3. Control: seated rest for 15min prior to exercise challenge&#xD;
&#xD;
      Control visit was always completed first. The order of the albuterol and interval warm-up&#xD;
      exercise visits was randomized.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was halted prematurely due to COVID 19.&#xD;
  </why_stopped>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>2x3 mixed ANOVA. 2 between groups: children with and without obesity. 3 within groups: control, interval warm-up, pretreatment with bronchodilator</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum % Change in Forced Expiratory Volume in the First Second (FEV1)</measure>
    <time_frame>The change in FEV1 will be assessed for up to 30 minutes after completing the exercise induced bronchoconstriction test</time_frame>
    <description>The change in FEV1 from before to after the exercise induced bronchoconstriction test.&#xD;
For the control condition, the change in FEV1 was measured from before the 6min exercise challenge test to up to 30 min after the exercise challenge test. The control condition was completed before participants were randomized to either albuterol or interval warm-up. This &quot;control&quot; condition is our reference condition because any improvement noted with albuterol or interval warm-up exercise should be compared against the control condition.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Asthma in Children</condition>
  <condition>Obesity, Childhood</condition>
  <condition>Exercise Induced Bronchospasm</condition>
  <arm_group>
    <arm_group_label>Albuterol first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order albuterol and then interval warm up (IWU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interval warm-up first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order is interval warm up (IWU) and then albuterol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol Sulfate</intervention_name>
    <description>Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test</description>
    <arm_group_label>Albuterol first</arm_group_label>
    <arm_group_label>Interval warm-up first</arm_group_label>
    <other_name>Ventolin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Interval Warm-up exercise</intervention_name>
    <description>Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test</description>
    <arm_group_label>Albuterol first</arm_group_label>
    <arm_group_label>Interval warm-up first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  no history of smoking, no history or evidence of heart disease, no history of&#xD;
             uncontrolled hypertension, no documented and/or diagnosed sleep disorders, no&#xD;
             diagnosed diabetes, no metabolic disorders, no history of significant mental illness,&#xD;
             no dietary restrictions, no serious health conditions, or no musculoskeletal&#xD;
             abnormality that would preclude exercise.&#xD;
&#xD;
          -  Normal weight children with a body mass index between the 16th and 84th percentile&#xD;
&#xD;
          -  Obese children with a body mass index &gt; 95th percentile but less than 170% above the&#xD;
             95th percentile and less than an absolute body mass index of 40 kg·m2&#xD;
&#xD;
          -  Pulmonary function criteria 1) forced vital capacity ≥ 80% predicted, 2) forced&#xD;
             expiratory volume in the first second (FEV1) ≥ 75% predicted, and total lung capacity&#xD;
             ≥ 80% predicted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with significant diseases other than obesity and mild asthma will be&#xD;
             excluded. A significant disease is defined as either a disease that in the opinion of&#xD;
             the PI or medical consultant Dr. Craig Nakamura may put the participant at risk&#xD;
             because of participation in the study or a disease that may influence the results of&#xD;
             the study or the patient's ability to participate in the study.&#xD;
&#xD;
          -  Children who cannot follow directions (e.g., eating before testing), adequately&#xD;
             perform procedures (e.g., pulmonary function tests), or keep appointments (e.g., no&#xD;
             shows for testing), will be excluded from study participation.&#xD;
&#xD;
          -  Because the risk of severe exercise induced bronchoconstriction increases in children&#xD;
             with moderate or severe obstructive airway disease, children with FEV1 &lt; 75% predicted&#xD;
             will be excluded from the study. Diagnosis of asthma (i.e., airway responsiveness with&#xD;
             reversible obstruction) will be established by spirometry (i.e., improvement of FEV1&#xD;
             of ≥8% after administration of bronchodilator).&#xD;
&#xD;
          -  Children without reversible airway obstruction will also be excluded from the study.&#xD;
&#xD;
          -  Children who have been hospitalized for an asthma exacerbation or who have taken oral&#xD;
             glucocorticoids for asthma in the past year, and children who have been admitted to an&#xD;
             intensive care unit or been intubated because of their asthma in the past five years,&#xD;
             will be excluded to reduce the risk of exacerbation during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dharini M Bhammar, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nevada, Las Vegas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Lung Specialists</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <results_first_submitted>April 22, 2021</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2021</results_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nevada, Las Vegas</investigator_affiliation>
    <investigator_full_name>Dharini M Bhammar</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>bronchoconstriction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Bronchial Spasm</mesh_term>
    <mesh_term>Asthma, Exercise-Induced</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no current plan to share individual participant data.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 10, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03586544/Prot_SAP_004.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 11, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03586544/ICF_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment:&#xD;
34 participants were screened for eligibility between 9/18/2018 - 3/13/2020. Participants were recruited from the Children's Lung Specialists Pediatric Pulmonology clinic.</recruitment_details>
      <pre_assignment_details>18 out of 34 enrolled participants were randomized. Of those not randomized (N=16), 10 did not meet inclusion criteria, 5 declined to participate, and 1 was not randomized because we terminated the study early. Of the 18 participants randomized, 2 did not complete all study visits: 1 because they declined to continue and 1 because of leg pain during exercise.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Order 1: Albuterol First, Interval Warm-up Second</title>
          <description>Participants first received albuterol on one day only. After at least 72 h, they completed the interval warm up on one day only. This was an acute study. There is no washout per se.</description>
        </group>
        <group group_id="P2">
          <title>Order 2: Interval Warm-up First, Albuterol Second</title>
          <description>Participants first completed interval warm up exercise on one day only. After at least 72 h, they recieved the albuterol (180ug) on one day only. This was an acute study. There is no washout per se.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis is shown for all randomized participants including the two participants who did not complete the interval warm-up first arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Albuterol First</title>
          <description>Children will complete an exercise induced bronchoconstriction test preceded by: 1) Control, 2) pretreatment with 'Albuterol' and 3) interval warm-up exercise and&#xD;
Control visit was always completed first. The order of albuterol and interval warm-up was randomized. In this arm, albuterol visit was completed first.</description>
        </group>
        <group group_id="B2">
          <title>Interval Warm up First</title>
          <description>Children will complete an exercise induced bronchoconstriction test preceded by: 1) Control, 2) pretreatment with 'Albuterol' and 3) interval warm-up exercise and&#xD;
Control visit was always completed first. The order of albuterol and interval warm-up was randomized. In this arm, interval warm-up visit was completed first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.6" spread="0.9"/>
                    <measurement group_id="B2" value="10.4" spread="1.0"/>
                    <measurement group_id="B3" value="10.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum % Change in Forced Expiratory Volume in the First Second (FEV1)</title>
        <description>The change in FEV1 from before to after the exercise induced bronchoconstriction test.&#xD;
For the control condition, the change in FEV1 was measured from before the 6min exercise challenge test to up to 30 min after the exercise challenge test. The control condition was completed before participants were randomized to either albuterol or interval warm-up. This &quot;control&quot; condition is our reference condition because any improvement noted with albuterol or interval warm-up exercise should be compared against the control condition.</description>
        <time_frame>The change in FEV1 will be assessed for up to 30 minutes after completing the exercise induced bronchoconstriction test</time_frame>
        <population>Two participants did not complete the interval warm-up arm and there results are not reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Albuterol First</title>
            <description>Albuterol first and then interval warm up</description>
          </group>
          <group group_id="O2">
            <title>Interval Warm-up First</title>
            <description>Interval warm-up first and then albuterol</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum % Change in Forced Expiratory Volume in the First Second (FEV1)</title>
          <description>The change in FEV1 from before to after the exercise induced bronchoconstriction test.&#xD;
For the control condition, the change in FEV1 was measured from before the 6min exercise challenge test to up to 30 min after the exercise challenge test. The control condition was completed before participants were randomized to either albuterol or interval warm-up. This &quot;control&quot; condition is our reference condition because any improvement noted with albuterol or interval warm-up exercise should be compared against the control condition.</description>
          <population>Two participants did not complete the interval warm-up arm and there results are not reported.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="7.47"/>
                    <measurement group_id="O2" value="-0.84" spread="12.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albuterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.98" spread="17.12"/>
                    <measurement group_id="O2" value="13.03" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interval Warm up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="14.90"/>
                    <measurement group_id="O2" value="-1.72" spread="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For our participants, the five visits were completed within 6.9 ± 2.4 weeks (Range: 3.6-11.1 weeks).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Albuterol Intervention</title>
          <description>180 ug of albuterol given on one day in this acute study.</description>
        </group>
        <group group_id="E2">
          <title>Interval Warm-up Intervention</title>
          <description>Interval warm-up exercise completed on one day in this acute study.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vocal cord dysfunction during exercise</sub_title>
                <description>Complained of shortness of breath towards the end of the exercise challenge test on the day of the interval warm-up visit. Evaluated by pediatric pulmonologist. Resolved spontaneously. Patient taught sniff and blow technique for future.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dharini Bhammar</name_or_title>
      <organization>The Ohio State University</organization>
      <phone>614-866-9467</phone>
      <email>dharini.bhammar@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

